Although frequently expressed in Epstein-Barr virus (EBV)-positive malignancies, the role that latent membrane protein 2A and 2B (LMP2A and LMP2B) have in the oncogenic process remains obscure. Here we show a novel function for these proteins in epithelial cells, namely, their ability to modulate signalling from type I/II interferon receptors (IFNRs). We show that LMP2Aand LMP2B-expressing epithelial cells show decreased responsiveness to interferon (IFN)a and IFNc, as assessed by STAT1 phosphorylation, ISGF3 and GAF-mediated binding to IFN-stimulated response element and IFNcactivated factor sequence elements and luciferase reporter activation. Transcriptional profiling highlighted the extent of this modulation, with both viral proteins impacting 'globally' on IFN-stimulated gene expression. Although not affecting the levels of cell-surface IFNRs, LMP2A and LMP2B accelerated the turnover of IFNRs through processes requiring endosome acidification. This function may form part of EBV's strategy to limit anti-viral responses and define a novel function for LMP2A and LMP2B in modulating signalling from receptors that participate in innate immune responses.
Introduction
Epstein-Barr virus (EBV) is a human gammaherpesvirus which is found as a widespread and largely asymptomatic infection throughout the world. The virus exploits the physiology of normal B-cell differentiation to persist within the memory B-cell pool of the immunocompetent host as a life-long latent infection. EBV replication occurs both in B cells and in mucosal epithelium lining the nasopharynx. It is the aberrant establishment of latent EBV infection at these sites that results in the development of both lymphoid and epithelial tumours (Young and Rickinson, 2004) . Of these malignancies, nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma (EBV-aGC) are numerically of greatest importance in global health terms. Both tumours have a multi-factorial aetiology involving virological (EBV), genetic and environmental components (Tao and Chan, 2007; Uozaki and Fukayama, 2008) . In NPC and EBV-aGC, viral gene expression restricted to EBNA1, EBER RNAs, the BamHIA transcripts and variable expression of the membrane proteins LMP1, LMP2A and LMP2B. This pattern of latent protein expression is distinct from that observed in EBVtransformed lymphoblastoid cell lines (LCL).
In EBV-infected B cells, LMP2A functions to promote viral latency, providing signals to ensure cell survival in the setting of compromised BCR signalling (Longnecker, 2000; Mancao and Hammerschmidt, 2007; Anderson and Longnecker, 2008a, b) . Although consistently detected in EBV-associated carcinomas, the role that LMP2A or LMP2B has in epithelial cell infection is unclear (Raab-Traub, 2002; Uozaki and Fukayama, 2008) . Although LMP2A does not affect the growth or differentiation of normal keratinizing epithelium (Longan and Longnecker, 2000) , when expressed in immortalized epithelial cell lines, it can enhance cell growth, survival and cellular differentiation through activation of the Ras/PI3K/Akt, Notch and b-catenin/ Wnt signalling pathways (Scholle et al., 2000; Morrison et al., 2003; Ikeda and Longnecker, 2007; Anderson and Longnecker, 2008a, b) . Thus, LMP2A appears to have a central function in the natural history of EBV infection whether it is the maintenance of persistent infection in the B lymphocyte pool or the more controversial contribution to epithelial cell transformation. The detailed function of LMP2B remains to be elucidated, although recent findings suggest that it serves to modulate the effects of LMP2A on BCR function, thereby rendering latently infected B lymphocytes susceptible to lytic re-activation (Rechsteiner et al., 2007 (Rechsteiner et al., , 2008 Rovedo and Longnecker, 2007) .
To date, much of the work on LMP2A function in epithelial cells has focused on its involvement in cell transformation. However, our previous studies have shown an ability of LMP2A to attenuate STAT activity in EBV-infected epithelial cells (Stewart et al., 2004) , raising the possibility that LMP2A may function to modulate signalling from interferon receptors (IFNRs).
This function may form part of EBV's strategy to limit anti-viral responses and defines a novel function for LMP2A in modulating signalling from receptors that participate in innate immune responses.
Interferons function as a first line of defence against viral infection (Katze, 2002) , serving to integrate innate and adaptive immune responses and limiting the replication and spread of viruses. IFNa and IFNb (type I IFNs) block viral replication by inhibiting cellular protein synthesis, stimulating the expression of proinflammatory cytokines and orchestrating cellular immune responses. Similarly, IFNg (type II IFN) has a key function in 'fine-tuning' the adaptive immune response. Whereas IFNa and IFNb share a common receptor, IFNAR, IFNg binds to IFNGR. IFNa/b and IFNg stimulate distinct classes of genes whose expression is regulated by binding of ISGF3 and GAF transcription factor complexes to the ISGF3-responsive IFN-stimulated response element (ISRE) and the IFNg-activated factor sequence (GAS) respectively, located within the promoter regions of IFN-stimulated genes (ISGs).
The complex nature of the human immune system has driven virus evolution, forcing viruses to develop strategies that override the growth inhibitory effects of IFNs. This is particularly relevant to persistent viruses, which, by definition, establish life-long infections within the infected host. Most, if not all, viruses encode proteins which function to target and inactivate the IFN signalling pathways, albeit temporarily. Certain viruses, such as Myxomavirus, express soluble decoy receptors that sequester IFNs, whereas the vast majority encode proteins, which target and inactivate the JAK/ STAT signalling proteins. For example, the Sendai virus C and Hpiv3V proteins prevent STAT phosphorylation, whereas the Simian virus 5 and Mumps virus V proteins target the STAT1 proteins for ubiquitin-mediated degradation. The V proteins encoded by the Nipah and hendra viruses block nuclear translocation of STAT proteins, thereby blocking the transcription of ISGs (Randall and Goodbourn, 2008) . Herpesviruses, which persist long term within the host, have also developed mechanisms to counteract the effects of IFN. Herpes simplex virus (HSV)-encoded US11 and ICP34.5, like the EBV-encoded EBER RNAs, target and inactivate the double-stranded RNA-activated protein kinase R (Cassady and Gross, 2002; Nanbo and Takada, 2002) . The BZLF1 protein of EBV has previously been reported to down-regulate transcription of the IFNGR during viral entry into lytic cycle, thereby protecting lytically infected cells from immune surveillance (Morrison et al., 2001) . KSHV has developed multiple strategies to counteract the effects of IFNs, expressing membrane proteins (K3, K5) which target cell-surface IFNRs (Li et al., 2007) and viral homologues of the interferon regulatory factors (IRFs), which function to antagonize host IRF function (Offermann, 2007) . Here we show that the EBV-encoded latent membrane proteins LMP2A and LMP2B attenuate IFN responses by targeting the IFNAR and IFNGR for degradation. Our findings define a novel function for these proteins in EBV biology that is distinct from those previously described.
Results

LMP2A and LMP2B inhibit both basal and IFN-stimulated transcription
In agreement with our previous observations (Stewart et al., 2004) , electrophoretic mobility shift assay (EMSA) confirmed reduced basal STAT activity in EBV-infected cells (Figure 1a ). That this repression was relieved in cells infected with an rEBV deleted for the LMP2A gene (LMP2A-rEBV) suggested that LMP2A might function to regulate negatively the JAK/STAT pathway in EBV-infected epithelial cells. To confirm that this effect was directly attributable to LMP2A, Ad/ AH and CNE2, we generated cells stably expressing LMP2A or LMP2B to examine the impact of LMP2A/ 2B on STAT activity in isolation from the whole virus (Allen et al., 2005) .
As shown in Figure 1b , a significant reduction in basal nuclear STAT (GAF) activity was observed in Ad/AH and CNE2 cells expressing LMP2A and LMP2B, confirming that this effect was attributable to expression of these proteins. That the non-signalling LMP2B isoform was also capable of modulating STAT activity indicated the cytosolic N terminus of LMP2A is not required for this effect.
Given that IFNs activate the JAK/STAT pathway as part of a host cell response to viral infection, we sought to examine the effects of LMP2A and LMP2B on IFN signalling in more detail. Nuclear extracts were prepared from IFNa-or IFNg-stimulated control and LMP2Aor LMP2B-expressing cells and EMSAs were performed using ISRE or GAS probes respectively. As shown in Figures 1c and d , EMSA revealed that both LMP2A and LMP2B suppressed basal and IFN-stimulated ISRE and GAS activity in both cell lines. In agreement with our previous observations, reduced nuclear ISRE and GAS binding activity was also observed in EBV-infected CNE2 cells (Figures 1e and f). To confirm that the decreased nuclear ISGF3/GAF binding observed by EMSA translated into attenuated IFN-mediated transcription, luciferase reporter assays were used to assay ISGF3 and GAF activity. Representative reporter assays (Figure 2a of IFNa and IFNg to stimulate both ISRE and GAS luciferase reporter activities in LMP2A-and LMP2Bexpressing CNE2 cells. Representative reporter assays ( Figure 2b ) also show similar reductions in ISRE and GAS luciferase reporter activity in EBV-infected CNE2 cells.
LMP2A and LMP2B attenuate JAK/STAT1 phosphorylation Given the ability of LMP2A and LMP2B to reduce the DNA-binding and transcriptional activity of ISGF3 and GAF complexes, we sought to investigate the integrity of the JAK/STAT pathway in LMP2A-and LMP2Bexpressing cells. Immunoblotting was performed on lysates prepared from IFNa-and IFNg-stimulated cells using an antiserum specific for phosphorylated STAT1 (p-STAT1 701 ). As shown in Figures 3a and b , in LMP2A-and LMP2B-expressing cells, IFNa and IFNg failed to induce STAT1 phosphorylation to the same extent as it did in control cells. Densitometric scanning revealed a 50 and 90% reduction in p-STAT1 30 min after IFNa and IFNg stimulation in LMP2Aand LMP2B-expressing cells. Similar reductions in JAK and TYK2 phosphorylation were also observed in response to IFNa or IFNg stimulation (Supplementary Figure S1A ). Although the levels of total STAT1 protein were similar between cell lines, the levels of JAK1, 2 and particularly, TYK2 were lower in LMP2A-and LMP2B-expressing cells (Supplementary Figure S1B ).
LMP2A and LMP2B exert global effects on IFN-induced transcription
The ability of LMP2A and LMP2B to attenuate IFN signalling in Ad/AH and CNE2 epithelial cells prompted us to examine their impact on IFNa-and IFNg-stimulated gene transcription. Gene transcription profiling was performed on IFNa-or IFNg-stimulated CNE2 cells using unstimulated counterparts as a reference. This analysis allowed us to determine whether the effects of LMP2A and LMP2B were 'global' or whether they target specific subsets of ISGs. The complete gene list obtained after microarray profiling is presented in Supplementary Tables ST1 and ST2 . When control cells were stimulated with IFNa for 6 h, 167 genes were significantly induced ( Figure 4a ). Of these 167 genes, only 99 genes were increased in LMP2A-expressing cells, 1 gene was significantly decreased, and expression of the remaining 67 genes unchanged relative to unstimulated cells. A similar trend was observed in LMP2B-expressing cells where only 113 out of the 167 genes were shown to be increased 6 h after IFNa stimulation. The activity of the remaining 54 genes was unchanged compared to the unstimulated LMP2B-expressing cells. This analysis indicated that LMP2A/2B attenuated the induction of a significant proportion of IFNa-stimulated genes. Similar effects were observed when LMP2A-or LMP2B-expressing cells were stimulated with IFNg. When control cells were stimulated with IFNg for 6 h, the expression of 432 genes was significantly increased (Figure 4b ). Of these 432 genes, only 290 genes were increased in LMP2A-expressing cells, with the remaining 142 genes remaining unchanged. A similar trend was observed in LMP2B-expressing cells where only 272 out of the 432 ISGs were increased after 6 h stimulation with IFNg. The activity of the remaining 160 genes was unchanged when compared to the unstimulated LMP2B-expressing cells. This further indicated that LMP2A and LMP2B were capable of attenuating the induction of IFNg-induced genes. Examination of the lists of the top 50 differentially regulated genes ( Supplementary Figures S2 and S3 ) revealed that LMP2A and LMP2B repressed the induction of many IFNa-and IFNg-stimulated targets whose expression was left unchanged or were unresponsive to IFNa or IFNg stimulation.
GAS-promoter luciferase assay
Plotting the distribution of fold changes of ISGs clearly highlighted the ability of LMP2A and LMP2B to attenuate the induction of global IFN-stimulated target genes. As shown in Figure 4a , IFNa stimulation of control cells resulted in a rightward shift in the distribution of fold changes. Here, the greater the fold change induction of ISGs, after IFN stimulation, the more significant the rightward shift. Comparing the distribution of fold changes in IFNa-stimulated LMP2A-or LMP2B-expressing cells, to that observed in IFNa-stimulated control cells, demonstrated retardation in the rightward shift. A similar trend was witnessed with IFNg stimulation (Figure 4b ). This further highlighted the ability of LMP2A and, to a lesser degree LMP2B, to attenuate global ISG activity in response to IFNa and IFNg stimulation.
To validate findings from the microarray profiling of IFN-stimulated cells, we selected a number of IFNa and IFNg target genes and analysed their expression by Q-PCR and western blotting. Representative analyses showed that the induction of a number of key IFNa and IFNg targets, including STAT1, IRF9, 2-5 OAS, MX2, GBP1 and IRF1, was reduced at the mRNA level in LMP2A-and LMP2B-expressing cells in response to IFNa or IFNg stimulation (Figure 4c ). Analysis of IFN-stimulated EBV-infected CNE2 cells revealed a similar reduction in selected ISG expression ( Figure 4c) . At the protein level, expression of IRF1, IRF7 and IRF9 was significantly reduced in LMP2Aand LMP2B-expressing cells both basally, and in response to IFNa or IFNg stimulation (Supplementary Figure S4A -C). LMP2A and LMP2B attenuate IFN signalling by enhancing IFN receptor turnover The ability of LMP2A and LMP2B to attenuate IFNmediated transcription indicates disruption of the IFN signalling pathway, yet the mechanism involved in this modulation remained unclear. The reduced levels of JAK1 and TYK2 in LMP2A-and LMP2B-expressing epithelial cells raised the possibility that LMP2A and LMP2B may attenuate IFN signalling by influencing the stability of IFNRs (Ragimbeau et al., 2003) . Immunoblotting of total cell lysates revealed a reduction in IFNAR1 and IFNGR1 levels in LMP2A-and LMP2Bexpressing cells compared to control cells (Figure 5a ). To analyse this in more detail, we performed immunofluorescence staining and confocal imaging on cells cultured in situ. As shown in Figure 5b , a significant reduction in the pools of intracellular IFNAR1 and IFNGR1 was observed in LMP2A-and LMP2Bexpressing cells compared to control cells (Figure 5b) , with a degree of overlap observed between LMP2A or LMP2B and the IFNRs in vesicular compartments (Figure 5b , right panel) . Despite the apparent reduction in intracellular pools of IFNAR1 and IFNGR1 in LMP2A-and LMP2B-expressing cells, flow cytometric analysis showed similar levels of expression on the surface of both control and LMP2A-or LMP2Bexpressing cells (Figure 5c ). These findings suggested that LMP2A and LMP2B might influence the turnover and/or stability of intracellular pools of IFNAR and IFNGR rather than affecting cell-surface stability or export to the plasma membrane. To investigate whether LMP2A and LMP2B accelerated the transit of IFNRs from the plasma membrane into lysosomes for subsequent degradation, we examined the rate of IFNGR internalization in situ. As shown in Figure 6a , incubation of cells with the anti-IFNGR1 antiserum at 4 1C decorated the surface of control, LMP2A-and LMP2Bexpressing cells equally (left panels). After 2 h incubation at 37 1C, the majority of cell-surface IFNGR1 had been internalized into large intracellular vesicles in control cells, whereas a weaker, more diffuse pattern of staining was observed in LMP2A-and LMP2Bexpressing cells (right panels).
The half-life of the IFNAR and IFNGR was then analysed using a cycloheximide (CHX)-based chase assay (Ragimbeau et al., 2003) . Total cellular lysates were prepared from CNE2 control and LMP2A-or LMP2B-expressing cells treated for various time points (0-6 h) with CHX. Immunoblotting of these lysates with antisera to IFNAR1 or IFNGR1 revealed that the stability of IFNRs was dramatically reduced in cells expressing LMP2A and, to a lesser extent LMP2B (Figure 6b ). Compared to IFNAR1, IFNGR1 was much less stable as indicated by a more rapid reduction in protein levels over the 6 h time course. Quantitation of the fluorescence intensities of IFNGR1 and IFNAR1 protein, normalizing against b-actin, revealed that the half-life of the IFNGR1 was approximately 4 h (3 h and 46 min) in control cells (Figure 6c ). Although the basal levels of IFNGR1 were lower in cells expressing LMP2A or LMP2B, the half-life of IFNGR1 was significantly reduced, being of the order of one and a half hours (Figure 6c ). A similar trend is observed with IFNAR1. In control cells, the half-life of the IFNAR1 was approximately 3 h (2 h and 59 min), yet this was significantly reduced in LMP2A-expressing cells. Surprisingly, although the basal level of IFNAR1 in LMP2B-expressing cells was much lower than that observed in control cells, its half-life more closely resembled that in control cells (Figure 6c) .
To investigate the possibility that LMP2A-or LMP2B-mediated turnover of IFNRs required endosomal targeting, we assayed the half-life of IFNGR1 under conditions in which endosome and lysosome functions were compromised. In these experiments, cells were treated with CHX for 2 h in combination with chloroquine and ammonium chloride (NH 4 Cl), compounds that inhibit endosomal and lysosomal acidification (Adachi et al., 2007) . Treatment of cells with chloroquine had a profound effect on IFNGR1 stability in all cell lines (Figure 6d ). Compared to CHX treatment alone, chloroquine treatment significantly blocked degradation of the IFNGR1 in LMP2A-and LMP2Bexpressing cells, whereas treatment with the lysosomal inhibitor, NH 4 Cl, had little or no effect. Similar effects to chloroquine were also observed with the broadspectrum protease inhibitor, MG132, which also increased stability of the IFNGR1 in all cell lines. Densitometric scanning of these blots confirmed the ability of chloroquine and MG132 to block the turnover and degradation of IFNGR1 in LMP2A/2B (Figure 6e ) where the expression levels returned to those observed in the control cells.
Discussion
In this report we show a novel function for LMP2A distinct from those previously reported, namely, an ability to attenuate signalling from type I and type II IFNRs. We also show that this function is not unique to Figure 4 Gene expression profiling confirming global attenuation of interferon-stimulated genes (ISGs) by LMP2A and LMP2B. (a and b) Analysis of microarray data from CNE2 control, LMP2A-and LMP2B-expressing cells 6 h after stimulation with (a) interferon (IFN)a or (b) IFNg. Tables were compiled to analyse ISGs that were significantly differentially increased, decreased or whose expression was unchanged in response to IFNa or IFNg. The distribution of fold change increase in ISG expression was plotted on a distribution graph using R (www.r-project.org). Data are shown for 6 h time points following IFNa or IFNg treatment. CNE2 control (red line), CNE2 LMP2A (green line) and CNE2 LMP2B (blue line). (c) Q-PCR validation confirmed reduced expression of selected ISGs (OAS2, IRF9, MX2, STAT1, GBP1 and IRF1) in LMP2A/2B-expressing cells and EBV-infected cells. Q-PCR data were normalized against GAPDH).
LMP2A, as the so-called 'signalling-defective' LMP2B protein is also capable of attenuating IFN signalling. The latter observation is intriguing given that the only known function of LMP2B is to antagonize LMP2A function in B cells (Rovedo and Longnecker, 2007) . The ability of these viral proteins to modulate IFN signalling is another example of a viral strategy for circumventing the innate immune response, an effect that is generally demonstrating similar levels of cell-surface IFNAR1 and IFNGR1 between and control and LMP2A-or LMP2B-expressiing cells. IFNAR1 and IFNGR1 expression is compared against the isotype control (solid black peak). Control (red), LMP2A (green) and LMP2B (blue). Figure 6 LMP2A and LMP2B increase the turnover and degradation of IFNAR1 and IFNGR1. (a) The extent of IFNGR internalization was monitored by following the fate of fluorescein isothiocyanate (FITC)-labelled IFNGR over time at 37 1C. Cells were incubated at 4 1C to label cell-surface IFNGR1 (left panels) and the fate of cell-surface IFNGR1 examined 2 h after incubation at 37 1C (right panels). Bar ¼ 10 mm. (b) LMP2A and LMP2B accelerate the turnover of IFNAR1 and IFNGR1. Control, LMP2A-and LMP2B-expressing cells were treated with 20 mg/ml cycloheximide (CHX) at 37 1C for various time points (0-6 h). Cells were harvested at the indicated time points and total cell lysates were immunoblotted with antisera specific for IFNAR1 or IFNGR1 followed by detection with IRDye 700-labelled goat anti-mouse/rabbit immunoglobulin. Immunoblots were analysed on the Odyssey infrared imaging system. To confirm equal protein loading, immunoblots were also probed with a monoclonal antibody (mAb) to b-actin. (c) LMP2A and LMP2B reduce the half-life of IFNAR1 and IFNGR1. The immunoblots shown in (b) were subjected to quantitation and graphs drawn to illustrate the half-lives of IFNAR1 and IFNGR1. In two independent experiments IFNGR1 and IFNAR1 were found to have half-lives of 3 h 46 min and 2 h 59 min in control cells, whereas in the presence of LMP2A and LMP2B this was reduced to 1 h 25 min and 1 h 52 min or 1 h 32 min and 2 h 42 min respectively. (d) LMP2A and LMP2B accelerate endocytic targeting of IFNGR to the lysosomes. Control, LMP2A-and LMP2B-expressing cells were treated for 2 h with 20 mg/ml cycloheximide (CHX) in the presence or absence of chloroquine, NH 4 Cl and MG132. Total cell lysates were subjected to immunoblotting with an antiserum specific for IFNGR1 followed by detection with a horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin. Equal protein loading was confirmed using an antibody to b-actin. (e) Densitometry was performed on the western blots in Figure 5d . Error bars represent standard deviations taken from three independent readings. exploited in persistent virus infections but which can, in the context of oncogenic viruses such as EBV, contribute to tumour development. Thus, although the ability to inhibit IFN signalling may form part of the virus's strategy to persist naturally in latently infected B lymphocytes, the inadvertent expression of these proteins in NPC, EBV-positive gastric carcinoma and Hodgkin's lymphoma tumour cells may contribute to oncogenic transformation by stimulating cell growth and limiting cellular responses to virus-infected cells.
Here we show that LMP2A and LMP2B attenuate IFN responses by targeting both the IFNRs. This strategy is more powerful than targeting individual signalling components such as the JAKs or STATs as exploited by viruses such as HSV, HCMV and HCV, as it produces a global blockade of IFN signalling. Immunoblotting, with 'activation-state'-specific antiserum confirmed that IFNa/b and IFNg's ability to stimulate JAK and STAT phosphorylation and the formation of nuclear ISGF3 and GAF transcription factor complexes was severely impaired in LMP2A-and LMP2B-expressing cells. This resulted in a robust attenuation of both IFNa/b-and IFNg-mediated transcription and a global repression in the induction of ISGs. The magnitude of this effect was clearly evident when transcriptional profiling was performed on IFNband IFNg-stimulated cells. Here, both qualitative and quantitative reductions in ISG expression were observed and further characterization of selected ISGs with established anti-viral activities was weakly induced in LMP2A-and LMP2B-expressing cells as well as EBVinfected CNE2 cells. The observation that EBV-infected CNE2 cells exhibit attenuated ISG activity (Figure 4c) , when compared to control cells, indicates that the low level LMP2A expression observed in these virally infected cells (Stewart et al., 2004) is likely to be sufficient to attenuate ISG activity.
Further investigations revealed that both LMP2A and LMP2B target IFNAR1 and IFNGR1 for degradation. Although it is presently unknown whether this involves direct physical interaction of LMP2A or LMP2B with IFN receptors, it appeared to relate to the ability of these viral proteins to enhance the rate of IFN receptor degradation. Although LMP2A or LMP2B did not influence the levels of cell-surface IFNAR1 and IFNGR1, immunofluorescence staining and immunoblotting revealed that the intracellular pools of IFNAR1 and IFNGR1 were greatly reduced in LMP2A-and LMP2B-expressing cells. The partial colocalization of LMP2A and LMP2B with IFNRs in late endosomes/ lysosomes suggests that these viral proteins may modulate the fate of internalized IFNRs, forcing them into a degradative arm of the endocytic pathway. This effect is reminiscent of the ability of the lytic cycle K3 and K5 proteins of KHSV to down-regulate the IFNGR which is achieved through the E3 ubiquitin ligase activity of these viral proteins (Rezaee et al., 2006; Li et al., 2007) .
A role for endosome-mediated degradation in IFNR turnover was confirmed as studies revealed decreased half-lives of both IFNAR1 and IFNGR1 in LMP2Aand LMP2B-expressing cells. Key functions for IFNR ubiquitination and endosomal targeting were established as treatment with MG132, a proteasomal inhibitor, and chloroquine, an endosome acidification inhibitor, completely blocked LMP2A-and LMP2Bmediated degradation of the IFNGR. Taken together these data suggest that LMP2A and LMP2B influence receptor stability by inducing receptor ubiquitination and the trafficking from endosomes to lysosomes. Although the mechanism by which LMP2A and LMP2B influence the endosome network is unclear, it may be linked to their association with lipid rafts (Dykstra et al., 2001; Ikeda and Longnecker, 2007) , cholesterol-rich microdomains that act as signalling platforms for many growth factor receptors (Ikeda and Longnecker, 2007) . As LMP2A and, presumably LMP2B, signal in a ligand-independent manner (Longnecker, 2000) , they may induce the turnover and degradation of receptors from these structures by enhancing early endosome formation. Such a scenario has been reported for the herpes virus saimiri Tip protein, which induces the turnover of the T-cell receptor (TCR) and CD4 on T lymphocytes by promoting their endocytosis from lipid rafts (Cho et al., 2006) . Like the TCR and CD4, the IFNRs, particularly IFNGR1, are recruited to lipid rafts on activation from where they are endocytosed (Claudinon et al., 2007) . Recently, a ligand-independent mechanism of IFNAR internalization and degradation has been reported (Liu et al., 2008) . Although phosphorylation and ubiquitination are required, it requires the activity of an as yet unidentified kinase distinct from TYK2. As LMP2A and LMP2B accelerate the turnover of IFNRs in the absence of IFN stimulation, they may stimulate the activity of this kinase to promote phosphorylation and ubiquitin-mediated lysosomal degradation.
An alternative possibility is that they modulate endosome function directly. Both proteins are highly hydrophobic transmembrane proteins that self-oligomerize and localize to endosomal compartments (Dawson et al., 2001) . Such a scenario is not without precedent, as the HPV-encoded E5 proteins have also been reported to modulate endosome function by associating with the vacuolar H þ -ATPase (Conrad et al., 1993) .
The fact that LMP2A and LMP2B are expressed in a significant proportion of NPC tumours suggests that, apart from their role in the maintenance of EBV persistence in healthy seropositive individuals, these proteins contribute to the continued growth of NPC tumour cells. A previous study has identified defects in antigen processing machinery and down-regulation of HLA class I antigen expression in EBV-positive NPC tumours (Ogino et al., 2007) , suggesting that during tumour progression NPC cells acquire mechanisms to escape immune recognition. Although it is presently unclear as to whether these two phenomena are linked, the ability of LMP2A and LMP2B to attenuate IFNa and IFNg signalling, as demonstrated in this study, may constitute an additional immune escape mechanism by which EBV protects malignant tumour cells from immune recognition and destruction by the hosts' immune system.
In conclusion, our data demonstrate a novel function for LMP2A and LMP2B in evading the IFN response thereby contributing to the persistence of EBV in healthy individuals and to the pathogenesis of virus-associated malignancies. A deeper understanding of the precise mechanisms responsible for this effect could lead to innovative approaches to treating EBV-positive tumours and to eradicating persistent virus infection.
Materials and methods
Cell lines and tissue culture CNE2 and Ad/AH cells were cultured in RPMI 1640 supplemented with 5% fetal calf serum and antibiotics (Sigma-Aldrich, Dorset, UK). Cell stably expressing LMP2A, LMP2B or a neomycin resistance cassette were generated as previously described (Allen et al., 2005) .
Antibodies and reagents
Antibodies to the phosphorylated forms of STAT1, JAK1, JAK2, TYK2, or IRF1 and IRF7 were purchased from Cell Signalling Technology (Danvers, MA, USA). Antibodies to STAT1, IRF9, IFNAR1, IFNGR1 and b-actin were purchased from Santa Cruz Biotechnology (Santa-Cruz, CA, USA). LMP2 staining was performed as previously described using human serum (Ba) displaying reactivity to LMP2A/2B (Allen et al., 2005) . Alexa Fluor-conjugated anti-mouse, anti-rabbit or anti-human immunoglobulins and IRDye 700-conjugated goat anti-mouse or anti-rabbit immunoglobulins were purchased from Invitrogen (Paisley, UK). Horseradish peroxidase (HRP)conjugated anti-mouse or anti-rabbit immunoglobulins were purchased from Dako (Glostrup, Denmark).
IFNa and IFNg (Peprotec, London, UK) were diluted to a final concentration of 100 ng/ml. CHX, NH 4 Cl, chloroquine (Sigma-Aldrich) and MG132 (Calbiochem, Gibbstown, NJ, USA) were used at final concentrations of 100 mM, 50 nM, 50 mM respectively.
Immunofluorescence staining and immunoblotting
Cells grown in situ on microscope slides (C.A. Hendley Essex Ltd, Essex, UK) were fixed, permeabilized and stained as previously described (Allen et al., 2005) . For examination of IFNAR1 and IFNGR1 half-life, immunoblotting was performed using IRD-700-or 800-labelled anti-mouse or anti-rabbit antibodies and membranes were scanned using the LI-COR Odyssey infrared imaging system (LI-COR Biotechnology, Lincoln, NE, USA). Fluorescence intensity was quantified and normalized to intensities of b-actin using the associated Odyssey software. All immunoblots were repeated on three independent occasions.
Electrophoretic mobility shift assay EMSA was performed as recommended by the manufacturer (LI-COR Biotechnology). Nuclear lysates (5 mg; prepared using the NE-PER nuclear extraction reagents (Pierce Biotechnology, Rockford, IL, USA)) were mixed with 50 nM of 5 0 -IRDye-700labelled oligonucleotides in LI-COR IRDye EMSA reagents for 30 min at room temperature. The 5 0 -3 0 sequences for the EMSA probes are as follows:
ISRE, (5 0 -GATCAGGAAATAGAAACTG-3 0 ), GAS, (5 0 -CATGTTATGCATATTCTTGTAAGTGCATG-3 0 ) Generic STAT, (5 0 -GACATTTCCCGTAAATCAT-3 0 ).
Reaction mixtures were resolved on 6% acrylamide-TBE gels and scanned using the LI-COR Odyssey infrared imaging system. Fluorescence intensity was quantitated using the associated Odyssey software. EMSAs were repeated on at least three independent occasions. ISRE and GAS luciferase reporter assays ISRE and GAS reporter assays were performed using the dual luciferase reporter assay (Promega, Hampshire, UK). The reporter plasmids pTAL-ISRE-luc (BD Biosciences) and GRR-5 (Beadling et al., 1996) or the control plasmids, pTAL-luc or pBL-luc were co-transfected with the Renilla plasmid to control for transfection efficiency. All dual luciferase assays represent an average of three independent experiments. Data are presented as the mean ± s.d.
Flow cytometry
Flow cytometry was performed as described previously (Dawson et al., 2000) . Briefly, single-cell suspensions were re-suspended in 50 ml of diluted primary antibody (IFNAR1 and IFNGR1 or isotype control) and incubated on ice for 60 min. Labelled receptors were visualized using Alexa Fluor 488-conjugated antimouse or anti-rabbit immunoglobulin Invitrogen. Immunofluorescence staining of cell-surface IFNR expression was analysed by flow cytometry using a Coulter EPICS XL FACScan. Data were processed using the WinMDI software package (http://facs. scripps.edu/software.html) to produce the relevant histograms.
Microarray analysis CNE2 cells were serum-starved for 16 h and either left unstimulated, or treated with IFNa or IFNg for 6 h. RNA from a series of biological triplicates was pooled and 10 mg of each was processed, labelled according to the Affymetrix protocol (Affymetrix, 2004) and hybridized to Affymetrix Human Genome U133 Plus 2 arrays. The scanned images of microarray chips were analysed using the GCOS (GeneChip Operating Software) from Affymetrix Inc. (Santa Clara, CA, USA) with the default settings except that the target signal was set to 100. The gene expression profile of IFNa-or IFNgstimulated cells was compared with that of unstimulated cells at the 6 h time point. Significantly differentially expressed probe sets were identified using GCOS pair-wise comparison algorithm. No fold change cut-off criterion was applied. The distribution of the data was analysed using the density function in R (http://www.r-project.org). Gene expression heat maps were generated using dChip (http://www.dchip.org) with the default settings.
